Sesen Bio, Inc (SESN)

Etorro trading 970x250
Sesen Bio, Inc (SESN) Logo

About Sesen Bio, Inc

Sesen Bio, Inc., a late-stage clinical company, focuses on designing, engineering, developing, and commercializing targeted fusion protein therapeutics (TFPTs) for the treatment patients with cancer. The company’s lead product candidates include Vicinium, a locally-administered targeted fusion protein that is in phase 3 clinical trials for the treatment of BCG-unresponsive non-muscle invasive bladder cancer (NMIBC); and VB6-845d, a systemically-administered product candidate for use in the treatment of various types of an anti-epithelial cell adhesion molecule (EpCAM)-positive solid tumors. It also develops Vicinium in combination with Durvalumab, which is in Phase I clinical trials for use in the treatment of BCG-unresponsive NMIBC; and Vicinium in combination with AstraZeneca’s checkpoint inhibitor for the treatment of squamous cell carcinoma of the head and neck. Sesen Bio, Inc. has an agreement with Leiden University Medical Center to co-develop an imaging agent. The company was formerly known as Eleven Biotherapeutics, Inc. and changed its name to Sesen Bio, Inc. in May 2018. Sesen Bio, Inc. was incorporated in 2008 and is headquartered in Cambridge, Massachusetts. Address: 245 First Street, Cambridge, MA, United States, 02142

Sesen Bio, Inc News and around…

Latest news about Sesen Bio, Inc (SESN) common stock and company :

Sanofi, Regeneron's Dupixent Gets FDA Nod for 4th Indication (Revised)
25 May, 2022 Yahoo! Finance

The FDA approves Sanofi's (SNY) Dupixent for treating adults and children aged 12 and older with eosinophilic esophagitis, a chronic, progressive inflammatory disease.

Biohaven's (BHVN) Zavegepant NDA for Migraine Accepted by FDA
24 May, 2022 Yahoo! Finance

The FDA accepts Biohaven's (BHVN) NDA seeking approval for its pipeline candidate, zavegepant, as an intra-nasal treatment for migraine. A decision is expected early next year.

Sanofi, Regeneron's Dupixent Gets FDA Nod for 4th Indication
23 May, 2022 Yahoo! Finance

The FDA approves Sanofi's (SNY) Dupixent for treating adults and children aged 12 and older with eosinophilic esophagitis, a chronic, progressive inflammatory disease.

Merck's (MRK) Keytruda Gets CHMP Nod for Expanded Melanoma Use
23 May, 2022 Yahoo! Finance

Merck's (MRK) anti-PD-1 therapy Keytruda nears potential approval as an adjuvant treatment for adolescent pediatric patients with stage IIB, IIC or III melanoma following complete resection.

Merck (MRK) Outperforms Industry This Year So Far: Here's Why
19 May, 2022 Yahoo! Finance

Strong sales of key products like Keytruda and Gardasil, a significant contribution from Lagevrio and positive pipeline/regulatory developments have been keeping Merck's (MRK) stock afloat in 2022.

AbbVie (ABBV) Buys Option Rights to NextGen Inflammation Drug
17 May, 2022 Yahoo! Finance

AbbVie (ABBV) receives the option to license worldwide rights for certain IL-2 muteins, including the next-generation inflammatory candidate, CUG252 from Cugene

Chimerix (CMRX) Plunges on Unfavorable Pipeline Updates
17 May, 2022 Yahoo! Finance

The development of Chimerix's (CMRX) lead candidate, ONC201, gets delayed as the FDA states that data from the retrospective study is unlikely to support an approval. The company ends the DSTAT program.

CRISPR (CRSP) Focuses on Pipeline Amid Lack of Marketed Drugs
16 May, 2022 Yahoo! Finance

While CRISPR Therapeutics' (CRSP) lead candidate is still a couple of years away from commercialization, it is highly dependent on collaboration revenues to fund its ongoing pipeline.

Lilly's (LLY) Diabetes Treatment Tirzepatide Gets FDA Nod
16 May, 2022 Yahoo! Finance

Lilly's (LLY) Mounjaro (tirzepatide) is a novel diabetes treatment, which has shown impressive blood sugar reductions and weight loss in a broad range of type II diabetes patients in the SURPASS studies.

Sesen Bio: Q1 Earnings Insights
09 May, 2022 FinancialContent

Sesen Bio (NASDAQ:SESN) reported its Q1 earnings results on Monday, May 9, 2022 at 08:00 AM. Here's what investors need ...

Sesen Bio Reports First Quarter 2022 Financial Results and Business Update
09 May, 2022 FinancialContent

Sesen Bio (Nasdaq: SESN), a late-stage clinical company developing targeted fusion protein therapeutics for the treatment of patients with cancer, today reported operating results for the first quarter ended March 31, 2022. During the quarter, the Company continued to engage with the US Food and Drug Administration (FDA) to identify an anticipated regulatory path toward potential resubmission of a Biologics License Application (BLA) for Vicineum™ for the treatment of non-muscle invasive bladder cancer (NMIBC). The Company has also initiated a process to review strategic alternatives with the goal of maximizing shareholder value.

12 Health Care Stocks Moving In Thursday's Intraday Session
05 May, 2022 FinancialContent

Gainers Better Therapeutics (NASDAQ:BTTX) stock increased by 44.5% to $3.13 during Thursday's regular session. ...

80 Biggest Movers From Yesterday
04 May, 2022 FinancialContent

Gainers Blue Water Vaccines, Inc. (NASDAQ: BWV) shares jumped 93.1% to close at $6.45 on Tuesday on above-average volume. XORTX ...

12 Health Care Stocks Moving In Tuesday's Intraday Session
03 May, 2022 FinancialContent

Gainers Blue Water Vaccines (NASDAQ:BWV) stock increased by 47.0% to $4.91 during Tuesday's regular session. The ...

The Daily Biotech Pulse: FDA's AdComm For Acadia's Pimavanserin, Review Issues For Spero's Tebipenem Application, Cortexyme Layoffs
03 May, 2022 FinancialContent

Here's a roundup of top developments in the biotech space over the last 24 hours. Stocks In Focus Acadia Announces FDA AdComm ...

Sesen Bio Provides Strategic Update
03 May, 2022 FinancialContent

Sesen Bio (Nasdaq: SESN), a late-stage clinical company developing targeted fusion protein therapeutics for the treatment of patients with cancer, today announced that it has initiated a process to review strategic alternatives with the goal of maximizing shareholder value. Potential strategic alternatives to be explored and evaluated during the review process may include the sale of the Company, a merger, acquisition or other business combination, a strategic partnership with one or more parties, or the licensing, sale or divestiture of some of the Company’s proprietary technologies. Pending any decision to undertake any strategic alternative, the Company is continuing its development activities in accordance with its existing business strategy.

Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Monday
02 May, 2022 FinancialContent

InvestorPlace - Stock Market News, Stock Advice & Trading Tips Welcome back to another busy day of trading as we break down the biggest pre-market stock movers investors need to know about for Monday! The post Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Monday appeared first on InvestorPlace. More From InvestorPlace Stock Prodigy Who Found NIO at $2… Says Buy THIS It doesn’t matter if you have $500 in savings or $5 million. Do this now. Get in Now on Tiny $3 ‘Forever Battery’ Stock Early Bitcoin Millionaire Reveals His Next Big Crypto Trade “On Air”

Stocks That Hit 52-Week Lows On Tuesday
26 Apr, 2022 FinancialContent

During Tuesday, 581 stocks hit new 52-week lows. Interesting Highlights From Today's 52-Week Lows Meta Platforms ...

Stocks That Hit 52-Week Lows On Wednesday
20 Apr, 2022 FinancialContent

On Wednesday, 160 companies hit new 52-week lows. Areas of Significance In Today's 52-Week Lows: Walt Disney ...

Sesen Bio: Q4 Earnings Insights
28 Feb, 2022 FinancialContent

Sesen Bio (NASDAQ:SESN) reported its Q4 earnings results on Monday, February 28, 2022 at 08:00 AM. Here's what ...

Sesen Bio Reports Fourth Quarter and Full-Year 2021 Financial Results and Anticipated Regulatory Path Forward for the Company’s Lead Product Candidate, Vicineum™
28 Feb, 2022 FinancialContent

Sesen Bio (Nasdaq: SESN), a late-stage clinical company developing targeted fusion protein therapeutics for the treatment of patients with cancer, today reported operating results for the fourth quarter and full year ended December 31, 2021. During the fourth quarter, the Company worked with the US Food and Drug Administration (FDA) to identify an anticipated regulatory path toward potential resubmission of a Biologics License Application (BLA) for the Company’s lead program, Vicineum™ for the treatment of non-muscle invasive carcinoma in situ (CIS) of the bladder in patients previously treated with adequate or less than adequate bacillus Calmette-Guérin (BCG).1

Notable Tuesday Option Activity: UIS, SESN, BLNK
22 Feb, 2022 FinancialContent

Among the underlying components of the Russell 3000 index, we saw noteworthy options trading volume today in Unisys Corp (UIS), where a total of 2,210 contracts have traded so far, representing approximately 221,000 underlying shares. That amounts to about 75.5% of UIS's average daily trading volume over the past month of 292,850 shares..

Is Sesen Bio (NASDAQ:SESN) In A Good Position To Deliver On Growth Plans?
17 Feb, 2022 Yahoo! Finance

Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...

Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Tuesday
25 Jan, 2022 FinancialContent

InvestorPlace - Stock Market News, Stock Advice & Trading Tips Good morning, investor! We're starting off the day right with a dive into the biggest pre-market stock movers for Tuesday! The post Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Tuesday appeared first on InvestorPlace. More From InvestorPlace Stock Prodigy Who Found NIO at $2… Says Buy THIS Now Man Who Called Black Monday: “Prepare Now.” #1 EV Stock Still Flying Under the Radar Interested in Crypto? Read This First...

Sesen Bio Further Enhances Team with Key Hires
10 Jan, 2022 FinancialContent

Sesen Bio (Nasdaq: SESN), a late-stage clinical company developing targeted fusion protein therapeutics for the treatment of patients with cancer, today announced the appointments of Minori Rosales, M.D., Ph.D. as Chief Development Officer as of January 24, 2022 and Stephanie Vigue as Director of Finance as of January 17, 2022.

12 Health Care Stocks Moving In Thursday's Pre-Market Session
06 Jan, 2022 FinancialContent

Gainers Freeline Therapeutics (NASDAQ:FRLN) stock increased by 58.1% to $3.1 during Thursday's pre-market session. ...

6 of the Best Penny Stocks Under $1 to Buy Now for 2022
22 Dec, 2021 FinancialContent

InvestorPlace - Stock Market News, Stock Advice & Trading Tips These penny stocks trading for under $1 per share all have strong chances of delivering stunning returns in the coming year. The post 6 of the Best Penny Stocks Under $1 to Buy Now for 2022 appeared first on InvestorPlace. More From InvestorPlace Stock Prodigy Who Found NIO at $2… Says Buy THIS Now Man Who Called Black Monday: “Prepare Now.” #1 EV Stock Still Flying Under the Radar Interested in Crypto? Read This First...

Why Sesen Bio Stock Got Slammed Today
09 Dec, 2021 FinancialContent

The company's hopeful words about its pipeline drug fell on deaf ears.

Sesen Bio To Conduct Additional Trial For Potential Resubmission Of Vicineum In Bladder Cancer
09 Dec, 2021 FinancialContent

Sesen Bio Inc(NASDAQ: SESN) hasoutlined its anticipated regulatory path forwardfor Vicineum for BCG-unresponsive ...

Sesen Bio Announces Anticipated Regulatory Path Forward for Vicineum™
09 Dec, 2021 FinancialContent

Sesen Bio (Nasdaq:SESN), a late-stage clinical company developing targeted fusion protein therapeutics for the treatment of patients with cancer, today announced its anticipated regulatory path forward for Vicineum™ for the treatment of BCG-unresponsive non-muscle invasive bladder cancer (NMIBC) following its Clinical Type A meeting with the US Food and Drug Administration (FDA), which occurred on December 8, 2021 (Clinical Type A Meeting).

Sesen Bio, Inc (SESN) is a NASDAQ Common Stock listed in , ,

970x250